Slide 1: Innovative ADCs with a New Payload: Amanitin
INNOVATIVE ADCS WITH A NEW PAYLOAD: AMANITIN Walter Miller, CFO
Slide 2: Safe Harbor: Forward Looking Statements
SAFE HARBOR FORWARD LOOKING STATEMENTS This communication contains certain forward-looking statements, competition from other biopharmaceutical, chemical and relating to the Company’s business, which can be identified by the pharmaceutical companies, environmental, health and safety matters, use of
Slide 3: Management Team with R&D and Pharma Experience
MANAGEMENT TEAM WITH R&D AND PHARMA EXPERIENCE András Strassz, MD Chief Medical Officer Dongzhou Jeffery Liu, PhD Chief Executive Officer More than 15 years experience in clinical drug development including roles at Sandoz, Amgen and biotech companies 25 years of industry experience of clinical and
Slide 4: Corporate Highlights
CORPORATE HIGHLIGHTS PROPRIETARY PAYLOADS, WHOLLY-OWNED ASSETS & PARTNERED ADCs Our Company Complete GMP Manufacturing Supply Chain • Clinical stage biotech • Heidelberg Pharma Group: 126 employees (staff reduction to ~ 30-35 until mid-2026) Technology and Asset Partnerships Maximize • Listed on Fra
Slide 5: Resistance Is One of the Biggest Challenges in Oncology
RESISTANCE IS ONE OF THE BIGGEST CHALLENGES IN ONCOLOGY 1 in 2 > 90% people will be diagnosed with of cancer deaths are caused by cancer in their lifetime drug resistance © Heidelberg Pharma AG 5
Slide 6: The Journey of Many Cancer Patients
THE JOURNEY OF MANY CANCER PATIENTS BEFORE TREATMENT TREATMENT RESISTANCE & RELAPSE Wagle, N. et al, J Clin Oncol. 2011; 29(22): 3085–3096 © 2011 by American Society of Clinical Oncology We need new drugs with new mode of action (MOA) to overcome resistance © Heidelberg Pharma AG 6
Slide 7: ATACs Address the Limitations of Current Cancer Therapies
ATACs ADDRESS THE LIMITATIONS OF CURRENT CANCER THERAPIES Cancer Diagnosis Treatment Long Term Response Outcome Tumor Relapse Standard Minimal Survival Therapy Cancer Stem Cells Increase (CSCs) survive CSCs survive Tumor bulk diminished Tumor Regrows Tumor ATAC Eradication Cure? Cancer Cell CSCs kil
Slide 8: The ATAC Platform Works Like a Guided Missile
THE ATAC PLATFORM WORKS LIKE A GUIDED MISSILE Enemy = Cancer Cells Missile's Warhead = Payload: α-Amanitin Targeting System = Antibody © Heidelberg Pharma AG 8
Slide 9: Strong IP Portfolio – HDP-101 Patent Estate
STRONG IP PORTFOLIO – HDP-101 PATENT ESTATE 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 2036 2037 2038 2039 2040 2041 2042 2043 2044 building blocks synthesis Payload humanized anti-BCMA mAbs, in-licensed ATAC Platform bioma
Slide 10: Lead Program: HDP-101 in Multiple Myeloma
LEAD PROGRAM: HDP-101 IN MULTIPLE MYELOMA MULTIPLE MYELOMA (MM) IS A TYPE OF BLOOD CANCER PHASE I/IIA CLINICAL TRIAL • … that develops from plasma cells in the bone marrow and can affect more than one part of the body. Phase I part: dose escalation (ongoing) • Cohorts of 2-6 patients are treated • I
Slide 11: HDP-101 Phase I/IIa Trial Design in Relapsed/Refractory Multiple Myeloma
HDP-101 Phase I/IIa Trial Design in Relapsed/Refractory Multiple Myeloma CX RP2D tbc Phase I: Dose Escalation Q3W intravenous dosing, BLRM Design 175 µg/kg Split 1st dose & Ongoing C9 premed*, then Q3W Arm C (+ premed) Q1W split C8 dosing Arm B Objectives 140 µg/kg Split 1st dose & C8 premed*, then
Slide 12: HDP-101 – Phase I Efficacy Data Cohort 5-8
HDP-101 – PHASE I EFFICACY DATA COHORT 5-8 10101_P40 C (112.5 µg/kg) (140 µg/kg) 10101_P37 C * Cohort 8 10101_P42 B 10101_P41 C Progressive disease (PD) 10101_P39 C Stable disease (SD) 10101_P38 B Minimal response (MR) 10101_P36 B Partial response (PR) 10101_P35 C Very good partial response (VGPR) S
Slide 13: HDP-101 Phase I/IIa: Preliminary Summary
HDP-101 PHASE I/IIa: PRELIMINARY SUMMARY 70% 57% Multiple efficacy endpoints show dose-dependent and 60% promising anti-cancer activity (Cohort 5-8): 50% • 38% ORR in Cohort 5 to 8 with 11 responders out of 29 patients 29% 40% 38% (7 PR, 1 VGPR and 3 sCR) • 3 patients with sCR (stringent complete re
Slide 14: ADCs: A Cancer Therapy Powerhouse
ADCS: A CANCER THERAPY POWERHOUSE 15 Approved ADC drugs globally 50+ ADCs FIH clinical trials (2023) 200+ Active ADC clinical trial stage ADCs are drug candidates blockbusters 11 Newly approved ADC Enhertu (USD 2.3bn)* Kadcyla (USD 2.2bn)* 51 Out-licensing deals in 2023 Adcetris (USD 1.7bn)* 55.5 US
Slide 15: HDP-101 Relevant Throughout the Spectrum of Treatment in Early Relapse
HDP-101 Relevant Throughout the Spectrum of Treatment in Early Relapse with Combination Regimens Potential Study Populations HDP-101 Regimens Near Term Priority Establish Post-BCMA Monotherapy Monotherapy in Late-line Setting Len-exposed (similar to DREAMM-8) Combination (IMiD + dex) Compete with Bl
Slide 16: Planned Studies Tap into Large, Growing Patient Populations
Planned Studies Tap into Large, Growing Patient Populations, with High Unmet Need to Prolong Survival Treatment Total Addressab. Range of Annual Peak 2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 Duration Population Size Analog Shares Addressab. (U.S.) (%, WW) US Market1 Accelerated approval Ful
Slide 17: Financials
FINANCIALS © Heidelberg Pharma AG 17
Slide 18: Key Financials Q3 2025 and FY 2024
KEY FINANCIALS Q3 2025 AND FY 2024 Guidance In EUR m Q3 2025 FY 2024 Operating Expenses Q3 2025 10/2025 7% 1% Sales revenue and other income 7.5 – 9.0 6.4 12.0 18% Operating expenses (36.0) – (40.0) (28.2) (32.6) Cost of sales (0.2) (1.8) R&D costs (21.0) (21.8) Administrative costs (5.0) (6.7) 67%
Slide 19: Listing Summary
LISTING SUMMARY PRIME STANDARD AT FRANKFURT STOCK EXCHANGE Current Market Cap EUR 130m – EUR 150m 52 Weeks - High/Low EUR 5.50 / 2.14 per share Number of Shares Outstanding EUR 46.8m Major Shareholders dievini & affiliated parties 44%, Huadong Medicine 35% Average #Shares Traded/Day ~ 10,000 – 13,00
Slide 20: Partial Monetization of Royalty Stream for TLX250-CDx
PARTIAL MONETIZATION OF ROYALTY STREAM FOR TLX250-CDx Partial monetization of royalty stream for TLX250-CDx an image agent for diagnostic use Key terms of the agreement between Heidelberg Pharma and HealthCare Royalty: • $25 m upfront payment at closing (March 2024), no repayment obligation in case
Slide 21: ADC Program Pipeline: Multiple Potential Value Drivers
ADC PROGRAM PIPELINE: MULTIPLE POTENTIAL VALUE DRIVERS Product Target Indication Research Preclinic Phase I Phase II Phase III Approval Partner HDP-101 BCMA Multiple Myeloma ------------------------------------------------------------------------------------------ Huadong (China+) ATAC pipeline HDP-
Slide 22: Reasons to Keep Us on Your Watch List
REASONS TO KEEP US ON YOUR WATCH LIST HDP-101 positive preliminary Highly dynamic ADC efficacy data and good tolerability environment with an in RRMM are a validation of our attractive global market that is Amanitin based technology for expected to grow future indications to USD 34 billion in 20321
Slide 23: Thank You for Your Attention!
THANK YOU FOR YOUR Heidelberg Pharma AG Ladenburg, Germany Tel.: +49 6203 10090 ATTENTION! investors@hdpharma.com investors@hdpharma.com www.heidelberg-pharma.com www.heidelberg-pharma.com
Slide 24: Supplement
®@, Heidelberg GaARMA SUPPLEMENT
Slide 25: Stock Chart & Newsflow
STOCK CHART & NEWSFLOW 04.09.2025 New Clinical Data on Lead ATAC Candidate 27.05.2025 HDP-101 to be Presented at International First Patient Dosed in Phase I Study of Myeloma Society Annual Meeting 2025 Amanitin-based ADC Candidate HDP- 102 for Non-Hodgkin Lymphoma 4.80 14.05.2025 23.10.2025 4.60 An
Slide 26: Strategic and Operational Focusing
STRATEGIC AND OPERATIONAL FOCUSING Strategic Focus: Heidelberg Pharma will concentrate all development activities on HDP-101, its lead Amanitin-based ADC candidate, currently in a Phase I/IIa trial for Multiple Myeloma. Pipeline Adjustments: • HDP-102 clinical program in Non-Hodgkin Lymphoma will be